BioSpace News Archive

ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, reported first quarter 2023 financial results and provided a corporate update.

Medpace Holdings, Inc. announced financial results for the first quarter ended March 31, 2023.

Cellectis (the “Company”) announced it has implemented the use of alemtuzumab as a Cellectis Investigational Medicinal Product (IMP), coded as CLLS52, as part of the lymphodepletion regimen for UCART22 in the BALLI-01 clinical trial in relapsed/refractory B-cell ALL, for UCART123 in the AMELI-01 clinical trial in relapsed/refractory AML, and for UCART20x22 in the NatHaLi-01 clinical trial in relapsed/refractory B-cell NHL.

Owens & Minor, Inc. plans to release financial results for the first quarter of 2023 on Friday, May 5, 2023, before trading begins on the New York Stock Exchange.